A Randomized Multicenter Double-Blind CT to Evaluate the Efficacy and Safety of Mycophenolate Mofetil . . .

Stopped The major and primary reason for the study termination is the observed reduced efficacy of CellCept compared to placebo.

Conditions

• Interstitial Cystitis
• Painful Bladder Syndrome

Interventions

• DRUG: Mycophenolate Mofetil
• DRUG: Mycofenolate Mofetil (MMF)
• DRUG: Placebo

Sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)